We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Curis Inc | NASDAQ:CRIS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 16.36 | 15.14 | 17.01 | 0 | 12:00:01 |
From May 2022 to May 2024
By Dean Seal
Curis Inc. said Thursday the U.S. Food and Drug Administration has lifted the partial clinical hold on its TakeAim Lymphoma study, a Phase 1/2 trial of emavusertib in patients with B-cell malignancies.
The cancer-focused biotechnology company announced the hold back in April, saying at the time that it was unexpected. The notification came from the FDA Division of Hematologic Malignancies 2, which regulates clinical studies in lymphoma.
The FDA lifted the hold after reviewing a comprehensive data package that Curis submitted, according to the company.
Chief Executive James Dentzer said the company is working to resume enrollment of new patients in the third quarter.
Shares soared 29.5% to $1.36 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
August 18, 2022 08:37 ET (12:37 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Curis Chart |
1 Month Curis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
